ProCE Banner Activity


Optimizing Outcomes for Patients With RCC

Text Module

Read this text module to learn about the most recent evidence for the treatment of advanced clear cell renal cell carcinoma and gain expert insight on optimizing therapy selection.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 07, 2023

Expiration: April 06, 2024



Katy Beckermann

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


This activity is supported by educationl grants from

AVEO Pharmaceuticals, Inc.

Bristol Myers Squibb

Exelixis, Inc.

Target Audience

This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with renal cell cancers.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients with RCC most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history

  • Plan neoadjuvant and adjuvant therapeutic approaches based on clinical data, current indications, and expert recommendations on systemic therapies for patients with RCC

  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration targeted and immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preference

  • Plan evidence-based and expert-recommended therapeutic sequencing strategies for patients with RCC

  • Manage specific disease-related complications or treatment-related adverse events associated with currently approved monotherapies and therapy combinations for advanced RCC

  • Select patients with RCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

Katy Beckermann, MD, PhD: consultant/advisor/speaker: Alpine Bioscience, Aravive, AstraZeneca, Aveo, Bristol-Myers Squibb, Exelixis, Merck, Sanofi, Seagen; researcher (paid to institution): Aravive, Arsenal, Bristol-Myers Squibb.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from April 07, 2023, through April 06, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. Study the educational activity online or printed out.
  4. Submit answers to the posttest questions and evaluation questions online.
    You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education 
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

Nursing Continuing Professional Development 
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours. 

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number -JA4008176-0000-23-091-H01-P 

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.